Oss, Netherlands
Oss, Netherlands

Time filter

Source Type

News Article | May 1, 2017
Site: www.businesswire.com

CAMBRIDGE, Mass.--(BUSINESS WIRE)--H3 Biomedicine Inc., a clinical stage biopharmaceutical company specializing in the discovery and development of precision medicines for oncology and a member of Eisai’s global Oncology Business Group, announced today that Lihua Yu, Ph.D., has been promoted to Chief Data Sciences Officer (CDSO). Dr. Yu previously served as H3 Biomedicine’s Vice President, Data Science and Information Technology. “Lihua’s appointment to Chief Data Sciences Officer fills a critical element in H3’s step towards building a comprehensive oncology pipeline and supporting the next generation of novel cancer drugs,” said Markus Warmuth, M.D., President and CEO of H3 Biomedicine. “Lihua’s proven commitment and expertise in establishing and expanding the use of data technology at H3 helped fuel the company’s growth through the integration of data science and cancer genomics, which has rapidly generated a superior informatics analysis engine.” In her new role, Dr. Yu will oversee H3 Biomedicine’s computational biology and data mining activities, including the management of the company’s cancer genomics and pharmacogenomics data. Additionally, she will supervise the identification and integration of all data analysis capabilities for discovery, preclinical and clinical data. Dr. Yu will also lead the Discovery Informatics team in developing genomics data management, integration, and exploration solutions to enable data mining and utilization across the company. Dr. Yu has over 17 years of experience in computational biology and bioinformatics, as well as deep knowledge in the area of cancer genomics and predictive biomarkers. Before joining H3 Biomedicine in 2011, Dr. Yu spent 12 years with AstraZeneca’s research and development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities. During her time there, she provided bioinformatics support to key areas of oncology drug discovery programs, including target identification and patient selection initiatives. “I am honored to serve as CDSO at such an exciting and pivotal time in the company’s trajectory. H3 continues to leverage distinct insights from cancer genomic data and patient information to advance our projects,” said Dr. Yu. “The strength of our science and success of our efforts to date are a direct result of H3’s understanding of and ability to explore genomic data through a BioIT eco-system, which remains an integral part of our genomics driven cancer drug discovery and development programs.” H3 Biomedicine is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments, which was established as a subsidiary of Eisai's U.S. pharmaceutical operation Eisai Inc. Leveraging this collaboration with Eisai Co., Ltd., who through this partnership provides essential research funding and access to the capabilities and resources of this global pharmaceutical company, H3 Biomedicine combines long-term vision with operational independence. Using modern synthetic chemistry, chemical biology, and human genetics, H3 Biomedicine seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. For more information, please visit http://www.h3biomedicine.com/.


Attributes its 146% revenue growth to the Zifo team’s collective strength and commitment towards customer’s success. Chennai, India, November 23, 2016 --( Zifo’s CEO, Raj Prakash G, credits the team’s valuable contributions and undeterred customer focus with the company’s revenue growth over the past three years. He said, "It’s a proud moment for Zifo – We have been ranked as the fastest growing organization for the fifth consecutive year! This consistency is reflective of our team’s collective strength and commitment towards customer’s success. As we run on this marathon, we have noticed that every leg has been marked with memorable events that make our journey exciting and fulfilling. Such recognitions are very refreshing and encouraging for our team." “Being one of the 50 fastest growing technology companies in India is an impressive accomplishment. We commend Zifo RnD Solutions for making the Deloitte Technology Fast50 India five times consecutively with phenomenal growth rates,” said Rajiv Sundar, Partner, Deloitte in India. About Zifo: Zifo is a Global R&D IT Solutions specialist providing best in class R&D solutions and services that drives efficiency across the Bio-Pharma spectrum. Zifo’s offerings span across Discovery Informatics, Lab Automation, Clinical Services, Translational Research and the Genomics Space. With global offices in US, UK, Europe, India and Japan, Zifo caters to a global customer base comprising 6 of the Top 10 leading Bio-Pharma companies. Zifo is vendor-neutral and provides technology solutions across various software and hardware platforms. Zifo RnD Solutions refers to the global organization and may refer to one or all of the affiliates of Zifo Technologies, each of which are separate legal entities in their respective geographies. About Deloitte Technology Fast50 India Progam: The Technology Fast50 India program, which was launched in 2005, is conducted by Deloitte Touche Tohmatsu India LLP (DTTILLP), and is part of a truly integrated Asia Pacific program recognizing the India’s fastest growing and most dynamic technology businesses (public and private) and includes all areas of technology - from internet to biotechnology, from medical and scientific to computers/hardware. The program recognizes the fastest growing technology companies in India based on their percentage revenue growth over the past three financial years. Chennai, India, November 23, 2016 --( PR.com )-- Zifo RnD Solutions today announced that it ranked Number 40 on the Deloitte Technology Fast 50™ India 2016, a ranking of the 50 fastest growing technology companies in India. Rankings are based on percentage revenue growth over three years. Zifo RnD Solutions grew 146 percent during this period.Zifo’s CEO, Raj Prakash G, credits the team’s valuable contributions and undeterred customer focus with the company’s revenue growth over the past three years. He said, "It’s a proud moment for Zifo – We have been ranked as the fastest growing organization for the fifth consecutive year! This consistency is reflective of our team’s collective strength and commitment towards customer’s success. As we run on this marathon, we have noticed that every leg has been marked with memorable events that make our journey exciting and fulfilling. Such recognitions are very refreshing and encouraging for our team."“Being one of the 50 fastest growing technology companies in India is an impressive accomplishment. We commend Zifo RnD Solutions for making the Deloitte Technology Fast50 India five times consecutively with phenomenal growth rates,” said Rajiv Sundar, Partner, Deloitte in India.About Zifo:Zifo is a Global R&D IT Solutions specialist providing best in class R&D solutions and services that drives efficiency across the Bio-Pharma spectrum. Zifo’s offerings span across Discovery Informatics, Lab Automation, Clinical Services, Translational Research and the Genomics Space. With global offices in US, UK, Europe, India and Japan, Zifo caters to a global customer base comprising 6 of the Top 10 leading Bio-Pharma companies. Zifo is vendor-neutral and provides technology solutions across various software and hardware platforms.Zifo RnD Solutions refers to the global organization and may refer to one or all of the affiliates of Zifo Technologies, each of which are separate legal entities in their respective geographies.About Deloitte Technology Fast50 India Progam:The Technology Fast50 India program, which was launched in 2005, is conducted by Deloitte Touche Tohmatsu India LLP (DTTILLP), and is part of a truly integrated Asia Pacific program recognizing the India’s fastest growing and most dynamic technology businesses (public and private) and includes all areas of technology - from internet to biotechnology, from medical and scientific to computers/hardware. The program recognizes the fastest growing technology companies in India based on their percentage revenue growth over the past three financial years. Click here to view the list of recent Press Releases from Zifo RnD Solutions


Baede E.J.,Discovery Informatics | Den Bekker E.,Discovery Informatics | Boiten J.-W.,Discovery Informatics | Cronin D.,Discovery Informatics | And 2 more authors.
Journal of Chemical Information and Modeling | Year: 2012

Drug discovery teams continuously have to decide which compounds to progress and which experiments to perform next, but the data required to make informed decisions is often scattered, inaccessible, or inconsistent. In particular, data tend to be stored and represented in a compound-centric or assay-centric manner rather than project-centric as often needed for effective use in drug discovery teams. The Integrated Project Views (IPV) system has been created to fill this gap; it integrates and consolidates data from various sources in a project-oriented manner. Its automatic gathering and updating of project data not only ensures that the information is comprehensive and available on a timely basis, but also improves the data consistency. Due to the lack of suitable off-the-shelf solutions, we were prompted to develop custom functionality and algorithms geared specifically to our drug discovery decision making process. In 10 years of usage, the resulting IPV application has become very well-accepted and appreciated, which is perhaps best evidenced by the observation that standalone Excel spreadsheets are largely eliminated from project team meetings. © 2012 American Chemical Society.


PubMed | Discovery Informatics
Type: Journal Article | Journal: Journal of chemical information and modeling | Year: 2012

Drug discovery teams continuously have to decide which compounds to progress and which experiments to perform next, but the data required to make informed decisions is often scattered, inaccessible, or inconsistent. In particular, data tend to be stored and represented in a compound-centric or assay-centric manner rather than project-centric as often needed for effective use in drug discovery teams. The Integrated Project Views (IPV) system has been created to fill this gap; it integrates and consolidates data from various sources in a project-oriented manner. Its automatic gathering and updating of project data not only ensures that the information is comprehensive and available on a timely basis, but also improves the data consistency. Due to the lack of suitable off-the-shelf solutions, we were prompted to develop custom functionality and algorithms geared specifically to our drug discovery decision making process. In 10 years of usage, the resulting IPV application has become very well-accepted and appreciated, which is perhaps best evidenced by the observation that standalone Excel spreadsheets are largely eliminated from project team meetings.

Loading Discovery Informatics collaborators
Loading Discovery Informatics collaborators